Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04166565 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04166565 · ClinicalTrials.gov record · last posted 2026-04-20

Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease

Study acronym: EMN19
StatusActive, Not Recruiting
PhasePhase 2
Started2019-10-31
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This trial will try to establish the feasibility and efficacy of the combination of DaraVCD in Multiple Myeloma (MM) patients presenting with extramedullary disease (EMD). The study will be conducted as a Phase II trial. Forty patients will be included in the study cohort. All patients will be followed closely for toxicities and response assessment. After completion of treatment, patients will be followed every 6 months for survival until 5 years after enrolment

Amendment record 4 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 4 times since 2019-11-14; most recent amendment 2026-04-15. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2022-11-07
Status change Recruiting→Active, Not Recruitingv2
Trial Details
NCT Number NCT04166565
Lead Sponsor Stichting European Myeloma Network
Collaborators: Janssen, LP
Conditions Multiple Myeloma, Extramedullary Plasmacytoma
Enrollment 41 participants
Start Date 2019-10-31
Primary Completion 2027-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-04-20